Prevention and Treatment of Bronchopulmonary Dysplasia

Chang Won Choi

doi:10.7599/hmr.2009.29.4.335

Journal List > Hanyang Med Rev > v.29(4) > 1044031

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Choi: Prevention and Treatment of Bronchopulmonary Dysplasia

Review Article

Hanyang Medical Reviews 2009; 29(4): 335-345.

Published online: 30 November 2009

DOI: https://doi.org/10.7599/hmr.2009.29.4.335

Prevention and Treatment of Bronchopulmonary Dysplasia

Chang Won Choi, M.D., Ph.D.

Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.

Corresponding author (choicw@snu.ac.kr)

Received 11 August 2009 Accepted 5 September 2009

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Despite recent remarkable advances in neonatal medicine, bronchopulmonary dysplasia (BPD) remains a major cause of morbidity and mortality in preterm infants. Due to increased survival of extremely low birth weight infants, the incidence of BPD has increased approximately 30% of extremely low birth weight infants. However, we have not discovered any single highly effective preventive therapy for BPD. This is due to an incomplete understanding of the molecular mechanisms involved in its pathogenesis. In this review, we review the current management strategies for preventing and treating BPD and then briefly propose novel approaches that are being investigated.

Keywords: bronchopulmonary dysplasia, Treatment, Prevention

Figures and Tables

Table 1

Levels of evidence and and recommendations for clinical use based on the guidelines developed by the US Preventive Services Task Force

Quoted from "Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia" by Bhandari A and Bhandari V7

Table 2

Existing approaches to prevent and/or treat bronchopulmonary dysplasia according to phase (early, evolving, and established)

The references noted refer to the sources of information for the requisite level of evidence and recommendation for clinical use.

PIP, peak inspiratory pressure; PEEP, positive end expiratory pressure; SNIPPV, synchronized nasal intermittent positive pressure ventilation.

Quoted from "Pitfalls, Problems, and Progress in Bronchopulmonary Dysplasia" by Bhandari A and Bhandari V7

References

1. Berger TM, Bachmann II, Adams M, Schubiger G. Impact of improved survival of very low-birth-weight infants on incidence and severity of bronchopulmonary dysplasia. Biol Neonate. 2004; 86:124–130.

2. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. NICHD-NHLBI-ORD Workshop. Am J Respir Crit Care Med. 2001; 163:1723–1729.

3. Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, Carlo WA. Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics. 2005; 115:e249–e254.

4. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med. 2006; 355:343–353.

5. Barrington KJ, Finer NN. Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol. 1998; 25:177–202.

6. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005; 115:655–661.

7. Bhandari A, Bhandari V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics. 2009; 123:1562–1573.

8. Greenough A. How has research in the past 5 years changed my clinical practice? Arch Dis Child Fetal Neonatal Ed. 2007; 92:F404–F407.

9. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2000; CD001456.

10. Kamlin CO, Davis PG. Long versus short inspiratory times in neonates receiving mechanical ventilation. Cochrane Database Syst Rev. 2004; CD004503.

11. Ambalavanan N, Carlo WA. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006; 30:192–199.

12. Bhandari V. Non-invasive ventilation of the sick neonate: evidence-based recommendations. J Neonatol. 2006; 20:212–221.

13. Miller JD, Carlo WA. Safety and effectiveness of permissive hypercapnia in the preterm infant. Curr Opin Pediatr. 2007; 19:142–144.

14. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev. 2003; CD000139.

15. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006; 354:2112–2121.

16. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehren-kranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA. National Institute of Child Health and Human Development Neonatal Research Network. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999; 340:1962–1968.

17. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev. 2007; CD000501.

18. Bhandari V, Brodsky N, Porat R. Improved outcome of extremely low birth weight infants with Tegaderm application to skin. J Perinatol. 2005; 25:276–281.

19. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2008; CD000503.

20. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005; 147:786–790.

21. Lai NM, Rajadurai SV, Tan KH. Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/chronic lung disease. Cochrane Database Syst Rev. 2006; CD005093.

22. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003; CD001145.

23. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (714 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003; CD001144.

24. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003; CD001146.

25. Baveja R, Christou H. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006; 30:209–218.

26. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, Mullen MP. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007; 120:1260–1269.

27. Bhandari A, Schramm CM, Kimble C, Pappagallo M, Hussain N. Effect of a short course of prednisolone in infants with oxygen-dependent bronchopulmonary dysplasia. Pediatrics. 2008; 121:e344–e349.

28. Ng GY, da S, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2001; CD003214.

29. Brundage KL, Mohsini KG, Froese AB, Fisher JT. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1990; 142:1137–1142.

30. Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, Epstein MF, Fitzhardinge PM, Hansen CB, Hansen TN. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics. 1987; 79:26–30.

31. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M, Susser M, Paneth N, Leviton A. The Neonatology Committee for the Developmental Network. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? Pediatrics. 2000; 105:1194–1201.

32. Aly H. Is there a strategy for preventing bronchopulmonary dysplasia? Absence of evidence is not evidence of absence. Pediatrics. 2007; 119:818–820.

33. Kinsella JP, Greenough A, Abman SH. Bronchopulmonary dysplasia. Lancet. 2006; 367:1421–1431.

34. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB. Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med. 2008; 358:700–708.

35. Davis PG, Lemyre B, De Paoli AG. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev. 2001; CD003212.

36. Kulkarni A, Ehrenkranz RA, Bhandari V. Effect of introduction of synchronized nasal intermittent positive-pressure ventilation in a neonatal intensive care unit on bronchopulmonary dysplasia and growth in preterm infants. Am J Perinatol. 2006; 23:233–240.

37. Bhandari A, Bhandari V. Bronchopulmonary dysplasia: an update. Indian J Pediatr. 2007; 74:73–77.

38. Thome UH, Carroll W, Wu TJ, Johnson RB, Roane C, Young D, Carlo WA. Outcome of extremely preterm infants randomized at birth to different PaCO2 targets during the first seven days of life. Biol Neonate. 2006; 90:218–225.

39. Greenough A, Sharma A. What is new in ventilation strategies for the neonate? Eur J Pediatr. 2007; 166:991–996.

40. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birthweight infants. N Engl J Med. 2002; 347:643–652.

41. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, Calvert SA. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med. 2002; 347:633–642.

42. Moriette G, Paris-Llado J, Walti H, Escande B, Magny JF, Cambonie G, Thiriez G, Cantagrel S, Lacaze-Masmonteil T, Storme L, Blanc T, Liet JM, Andre C, Salanave B, Breart G. Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics. 2001; 107:363–372.

43. McCallion N, Davis PG, Morley CJ. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev. 2005; CD003666.

44. Deulofeut R, Critz A, Adams-Chapman I, Sola A. Avoiding hyperoxia in infants < or = 1250 g is associated with improved short- and long-term outcomes. J Perinatol. 2006; 26:700–705.

45. Greenspan JS, Goldsmith JP. Oxygen therapy in preterm infants: hitting the target. Pediatrics. 2006; 118:1740–1741.

46. Moya F, Sinha S, Gadzinowski J, d'Agostino R, Segal R, Guardia C, Mazela J, Liu G. One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics. 2007; 119:e1361–e1370.

47. Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol. 1995; 173:322–335.

48. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006; CD004454.

49. Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002; 109:330–338.

50. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki HJ, Leach CL, Backstrom C, Shaffer ML. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004; 114:1649–1657.

51. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2007; CD001969.

52. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996; 97:210–215.

53. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 2005; 24:1033–1039.

54. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev. 2003; CD003744.

55. Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res. 2007; 8:41.

56. Brion LP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2002; CD001817.

57. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011; CD001453.

58. Mataloun MM, Rebello CM, Mascaretti RS, Dohlnikoff M, Leone CR. Pulmonary responses to nutritional restriction and hyperoxia in premature rabbits. J Pediatr (Rio J). 2006; 82:179–185.

59. Biniwale MA, Ehrenkranz RA. The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006; 30:200–208.

60. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med. 2006; 355:354–364.

61. Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. J Pediatr. 2007; 151:10–15.

62. Steinhorn RH, Kinsella JP. Use of inhaled nitric oxide in the preterm infant. Neoreviews. 2007; 8:e247–e253.

63. Truog WE. Inhaled nitric oxide for the prevention of bronchopulmonary dysplasia. Expert Opin Pharmacother. 2007; 8:1505–1513.

64. Howlett A, Ohlsson A. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2003; CD000366.

65. Davis JM. Role of oxidant injury in the pathogenesis of neonatal lung disease. Acta Paediatr Suppl. 2002; 91:23–25.

66. Suresh GK, Davis JM, Soll RF. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev. 2001; CD001968.

67. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, Jonsbo F, Esberg G, Stovring S, Kjartansson S, Stiris T, Lossius K, Virkola K, Fellman V. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr. 2003; 143:713–719.

68. Shah P, Ohlsson A. Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2001; CD002775.

69. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, Davis JM. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res. 2005; 58:15–21.

70. Thebaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007; 175:978–985.

TOOLS

Similar articles